Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4179.70 +0.2% SILVER 57.15 −0.0% COPPER 6.56 +0.1% OIL 99.20 +1.3% PALLADIUM 1114.50 −1.2% CCMM 0.520 +7.2% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.520 +0.0% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.64 −1.2% CASA 0.060 +0.0% DRY 0.220 +2.3% GOLD 4179.70 +0.2% SILVER 57.15 −0.0% COPPER 6.56 +0.1% OIL 99.20 +1.3% PALLADIUM 1114.50 −1.2% CCMM 0.520 +7.2% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.640 −1.5% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.520 +0.0% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.64 −1.2% CASA 0.060 +0.0% DRY 0.220 +2.3%

Healthcare

Page 61
  1. Feb 13, 2026 · 08:09 · MDNA

    Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

    Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

    01
  2. Feb 13, 2026 · 07:31 · HELP

    HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    02
  3. Feb 13, 2026 · 07:00 · CNVI

    Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging

    Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging

    03
  4. Feb 13, 2026 · 01:36 · 4565

    Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

    Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

    04
  5. Feb 12, 2026 · 19:58 · GSD

    Devonian preclinical data support Thykamine

    Devonian preclinical data support Thykamine

    05
  6. Feb 12, 2026 · 19:49 · ONCO

    Onco-Innovations lowers per-unit price of placement

    Onco-Innovations lowers per-unit price of placement

    06
  7. Feb 12, 2026 · 18:15 · APLI

    Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

    Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

    07
  8. Feb 12, 2026 · 17:17 · MBX

    Microbix loses $1.16-million in fiscal Q1

    Microbix loses $1.16-million in fiscal Q1

    08
  9. Feb 12, 2026 · 17:14 · KNE

    Kane Biotech revives commercial activity for revyve gel

    Kane Biotech revives commercial activity for revyve gel

    09
  10. Feb 12, 2026 · 12:38 · MSCL

    Satellos says first participant dosed in DMD study

    Satellos says first participant dosed in DMD study

    10
  11. Feb 12, 2026 · 12:05 · CHS

    Comprehensive Healthcare closes $3.5M first tranche

    Comprehensive Healthcare closes $3.5M first tranche

    11
  12. Feb 12, 2026 · 09:00 · GSD

    Devonian reports additional molecular data from MASH liver study

    Devonian reports additional molecular data from MASH liver study

    12
  13. Feb 12, 2026 · 09:00 · ONCO

    Onco-Innovations Announces Amendment to Private Placement Pricing

    Onco-Innovations Announces Amendment to Private Placement Pricing

    13
  14. Feb 12, 2026 · 07:25 · KNE

    Kane Biotech Restarts Commercial Activities and Strengthens North American Management

    Kane Biotech Restarts Commercial Activities and Strengthens North American Management

    14
← Newer Older →